Faron Pharmaceuticals Oy
FARN.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | – | – | – | – |
| R&D Expenses | £4 | £5 | £7 | £11 |
| G&A Expenses | £2 | £2 | £5 | £4 |
| SG&A Expenses | £2 | £2 | £5 | £5 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | -£0 |
| Operating Expenses | £6 | £7 | £11 | £16 |
| Operating Income | -£6 | -£7 | -£11 | -£16 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -£4 | -£4 | -£3 | -£1 |
| Pre-Tax Income | -£10 | -£12 | -£14 | -£17 |
| Tax Expense | £0 | -£0 | £0 | £0 |
| Net Income | -£10 | -£12 | -£14 | -£17 |
| % Margin | – | – | – | – |
| EPS | -0.09 | -0.054 | -0.1 | -0.13 |
| % Growth | -67.1% | 45.9% | 23.1% | – |
| EPS Diluted | -0.09 | -0.054 | -0.1 | -0.13 |
| Weighted Avg Shares Out | 107 | 88,518 | 70,452 | 81,159 |
| Weighted Avg Shares Out Dil | 107 | 88,518 | 70,452 | 81,159 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £1 |
| Interest Expense | £4 | £4 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£6 | -£7 | -£11 | -£16 |
| % Margin | – | – | – | – |